

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/21	A2	(11) International Publication Number: WO 00/00216 (43) International Publication Date: 6 January 2000 (06.01.00)
<p>(21) International Application Number: PCT/EP99/04913</p> <p>(22) International Filing Date: 28 June 1999 (28.06.99)</p> <p>(30) Priority Data: 98420110.3 26 June 1998 (26.06.98) EP 98420111.1 26 June 1998 (26.06.98) EP</p> <p>(71) Applicant (<i>for all designated States except US</i>): PASTEUR MERIEUX SERUMS ET VACCINS [FR/FR]; 58, avenue Leclerc, F-69007 Lyon (FR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): CHEVALIER, Michel [FR/FR]; 19, rue de la Guillotière, F-38270 Beurepaire (FR). MEIGNIER, Bernard [FR/FR]; 26, rue du 8 mai 45, F-69510 Thurins (FR). MOSTE, Catherine [FR/FR]; 7, avenue Louis Momet, F-69260 Charbonnières-les-Bains (FR). SAMBHARA, Suryaprakash [CA/CA]; 50 Harness Circle, Markham, Ontario L3S 1Y1 (CA).</p> <p>(74) Agent: AYROLES, Marie-Pauline; Pasteur Mérieux Sérums et Vaccins, 58, avenue Leclerc, F-69007 Lyon (FR).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: USE OF POXVIRUSES AS ENHANCER OF SPECIFIC IMMUNITY</p> <p>(57) Abstract</p> <p>The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine <i>e.g.</i>, a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Use of poxviruses as enhancer of specific immunity

The present invention relates to a method for enhancing the specific immune response against an immunogenic compound, which comprises administering the immunogenic
5 compound together with a poxvirus, recombinant or not.

Smallpox, a human infectious disease due to a vaccinia virus, was declared eradicated from the globe in 1980. This unique success was made possible by the availability of an effective virus-attenuated vaccine. Concurrent with the smallpox
10 eradication and the cessation of vaccination, a new use for the vaccinia virus was proposed (Panicali & Paoletti, PNAS (1982) 79: 4927). Utilizing molecular cloning techniques, it became possible to express genes from foreign pathogens in vaccinia virus providing new approaches to vaccination.

15 Since then, the original technology has been applied to the whole poxvirus family, including not only the vaccinia virus but also avipoxviruses such as fowlpox and canarypox. In order to address the issue of safety, a strategy was developed to genetically engineer a highly attenuated vaccinia virus such as the Copenhagen strain that would still retain the ability to induce vigorous immunological response against extrinsic antigens.
20 A number of poxvirus constructions have been tested in clinical trials. As a matter of example, they include recombinant vaccinia and canarypoxviruses expressing Human Immunodeficiency Virus (HIV) or *Plasmodium falciparum* antigens. Further, it has already been proposed to combine, in an immunization protocol, a prime-administration using a recombinant poxvirus vector and booster-administrations of the purified
25 polypeptide as encoded by the recombinant vector (See *e.g.*, Excler & Plotkin, AIDS (1997) 11 (suppl. A): S127). Such immunization protocols are commonly referred as prime-boost protocols and are very advantageous in a number of cases, in particular for AIDS treatment or prevention.

30 Prime-boost protocols are however unpractical both for physicians, manufacturers and sellers, in that they require two different pharmaceutical products that have to be each identified and licensed for their specific use (priming or boost).

It has now been found that poxvirus particles may be useful as enhancer of specific immunity. Indeed, it has been observed that the immune response against a vaccinal antigen, such as an HIV or an influenza virus protein, is enhanced, when it is
5 mixed with a poxvirus, recombinant or not. Additionally, It has also been found that an immunization protocol exclusively using a composition comprising a polypeptide and a poxvirus encoding this polypeptide, may be just as good as a prime-boost protocol. It has also surprisingly been found that the observed immunization effect is not a mere additional effect, but results from a synergism effect between the two components.

10

Therefore, the invention provides for:

- (i) The use of a poxvirus for the manufacture of a pharmaceutical composition comprising an immunogenic compound for inducing an immune response in a
15 vertebrate, wherein the poxvirus is able to enhance a specific immune response to the immunogenic compound.
- (ii) The use of a mixture comprising (a) an immunogenic compound which comprises at least one antigenic determinant characteristic of a pathogenic
20 microorganism or is cross-reactive with a tumor-associated antigen (TAA) and (b) a poxvirus; in the manufacture of a medicament to be administered to a vertebrate for treating or preventing an infection induced by the pathogenic microorganism or a tumoral disorder characterized by the malignant expression of the TAA; whereby said poxvirus enhances the specific immune response of the
25 vertebrate against said immunogenic compound.
- (iii) A pharmaceutical composition comprising (a) an immunogenic compound and (b) a poxvirus encoding an heterologous polypeptide which is selected from the
30 group consisting of adhesion molecules, co-immunostimulatory molecules, apoptotic factors, cytokines, chemokines and growth hormones.

- 5
- (iv) A pharmaceutical composition comprising (a) an immunogenic compound which is a first polypeptide and (b) a poxvirus encoding an heterologous polypeptide, which has an amino acid sequence identical to the amino acid sequence of the first polypeptide.
- 10
- (v) A pharmaceutical composition comprising (a) an immunogenic compound which is a DNA plasmid encoding a first polypeptide and (b) a poxvirus encoding a second heterologous polypeptide, which has an amino acid sequence identical to the amino acid sequence of the first polypeptide.
- 15
- (vi) A method for enhancing the specific immune response of a vertebrate to an immunogenic compound, which comprises administering to the vertebrate the immunogenic compound together with a poxvirus, whereby the poxvirus enhances the specific immune response to the immunogenic compound.
- 20
- (vii) A method for treating or preventing in a vertebrate, a disorder either induced by a pathogenic microorganism or characterized by the malignant expression of a T.A.A, which comprises administering to the vertebrate, (a) an immunogenic compound which comprises at least one antigen determinant characteristic of the pathogenic microorganism or a tumor-associated antigen together with (b) a poxvirus; whereby a specific immune response to the immunogenic compound is induced in the vertebrate and whereby the poxvirus enhances the specific immune response.
- 25
- (viii) A method for enhancing the specific "in vitro" immunostimulation of cells from an immune system against a specific immunogenic compound, which comprises (a) recovering cells from a vertebrate, (b) "in vitro" incubating the cells with the immunogenic compound together with a poxvirus, whereby the cells are immunostimulated against the immunogenic compound and whereby the poxvirus enhances the immunostimulation and (c) administering the
- 30
- immunostimulated cells obtained from step (b) to a vertebrate.

In a general manner, there exist two types of immunity: the innate immunity and the acquired immunity. The former which is phylogenetically older brings into play soluble molecules, *i.a.* complement factors and cells, such as NK cells or macrophages, which are innately programmed to detect noxious substances produced by pathogenic microorganisms and to provide for rapid but often incomplete antimicrobial host defense. The innate immune system intervenes as the first line of defense when an infectious agent attacks an individual. On the other hand, the innate immune system can not be educated by the antigens expressed by the pathogenic microorganisms or tumor cells during the life of an individual and in this respect, the innate immunity is confounded with the natural immunity. By contrast, the acquired immune system brings into play antigen-specific B and T lymphocyte clones the affinity of which increases by the time consecutively to repeated contacts with the specific antigen. Moreover, some of them behave as memory lymphocytes, since they have a long lasting life and are able to proliferate and expand rapidly consecutively to a further contact with a specific antigen, so that these memory lymphocytes contribute to the long term protection of an individual to infectious microorganisms. An essential goal of vaccination is to provide for these memory lymphocytes.

Accordingly, by "specific immune response" is meant a specific humoral and /or a specific cellular immune response against the immunogenic compound of the pharmaceutical composition. In the present invention, the specific humoral immune response includes both systemic and mucosal antibody responses since, to feature the humoral response, one may refer to all types of specific antibodies, *i.e.* IgM, all subclasses of IgG and IgA, that may be elicited by the pharmaceutical composition. The specific lymphoproliferative response and the specific cytotoxic T lymphocyte (CTL) response preferentially are the main parameters of the specific cellular immune response.

For use in the present invention, the immunogenic compound may be a chemical or a biological material that is able to induce a humoral or cellular immune response in a vertebrate. A biological material may be *e.g.*, an attenuated, inactivated or killed virus (to the exception of a poxvirus); a bacterial strain; a pseudovirion; a bacterial extract; a capsular polysaccharides; a peptide or a polypeptide found tumor-associated, cross-reactive with a TAA or characteristic of a pathogenic agent; or a DNA plasmid encoding

a peptide or a polypeptide as described above. As an example of chemical material, a hapten coupled to a carrier protein is cited.

By "hapten" is meant a molecule, generally of low molecular weight, which is
5 unable to trigger an antibody response by itself, but capable, after coupling with a carrier, to induce a specific antibody response which interacts specifically with the hapten molecule. For use in the present invention, such an hapten may be a peptide which amino acid sequence is at least 5 to 6 amino acid long (minimal size of an epitope) but of low molecular weight, a chemical molecule (such as dinitrophenol), or a drug. In a particular
10 embodiment of the present invention, a mixture according to the invention may be intended to treat drug addiction and to this end, may comprise a poxvirus, mixed with a drug, such as cocaine, coupled to a carrier molecule to induce an antibody response against the drug, in order to hamper both its fixation on the target cells, tissues or organs and the triggering of its narcotic effects. Methods of coupling a hapten to a carrier
15 molecule are of common use for a man skilled in the art.

By "polypeptide" or "protein" is meant any chain of amino acids, regardless of the length or post-translational modification (*e.g.*, glycosylation or phosphorylation). Both terms are used interchangeably in the present application.

20

Advantageously, immunogenic polypeptides may be polypeptides characteristic of a pathogenic microorganism *i.e.* a virus, bacteria or an eucaryotic parasite, or tumor-associated antigens (that are mammalian or avian antigens which are not normally expressed; their malignant expression is characteristic of a tumoral disorder) such as
25 tyrosinase, the MAGE protein family, the CEA, the ras protein, mutated or not, the p53 protein, mutated or not, Muc1, CEA and pSA.

For use in the present invention, immunogenic polypeptides may have amino acid sequences corresponding to the complete or partial sequence of naturally occurring
30 polypeptides. They may also have a sequence derived by amino acid deletion, addition or substitution from the naturally occurring sequences as far as they behave as immunologic equivalents *i.e.*, they are able to induce an immune response against the pathogenic microorganisms from which they derive or against the tumor. In other terms, an

immunogenic polypeptide is also meant to include any polypeptide that is immunologically cross-reactive with a naturally occurring polypeptide found in a pathogenic agent or tumor-associated.

- 5 By "immunologically cross-reactive polypeptides" is meant polypeptides that can be recognized by antibodies, *e.g.* polyclonal antibodies, raised against each of the polypeptides used separately, and advantageously in a substantially purified form.

As a matter of example, the polypeptide may be an HIV antigen such as the env, gag, pol or nef protein. An HIV antigen is also meant to include any polypeptide that is immunologically cross-reactive with a naturally occurring HIV protein. For example, an HIV env protein may be the gp160 env precursor, or the gp120 or gp41 sub-unit. The gp160 precursor may be a soluble, non-cleavable precursor obtained by mutation of the cleavage site and deletion of the transmembrane region as described in U.S. Patent No
10 5,672,689. The precursor may also be truncated so that the C-terminal part of the gp41 region is removed (intracytoplasmic domain). The precursor may also be a hybrid precursor, combining in a single molecule, env sequences from various HIV strains. An HIV gag antigen may be the complete p55 precursor, the p13, p18 or p25 that naturally derive from p55, or any immunogenic gag protein fragment. In fact, a large variety of
15 polypeptides may be substituted for the naturally occurring HIV env, gag, pol or nef proteins, yet retaining their immunogenic properties.

As an additional example the polypeptide may be an influenza peptide or polypeptide which comprises the virus envelope components such as the haemagglutinin
25 and the neuraminidase and the virus internal components such as the protein M, the non-structural proteins and the nucleoprotein. An influenza peptide or polypeptide is also meant to include any precursor form of the mature envelope or internal proteins that are immunologically cross reactive with them. Likewise, the polypeptide or peptide may be any kind of haemagglutinin or neuraminidase of the influenza virus since there are
30 numerous antigenic variants of these two proteins.

For use in the present invention, the polypeptide characteristic of a pathogenic agent that is physically present in the composition may be purified from the pathogenic

agent itself or recombinantly produced. Advantageously tumor-associated antigens (TAAs) as well will be produced by recombinant means. Standard expression vectors, promoters, terminators, etc and recombinant methods are now of common use for a man skilled in the art and recombinant expression can be readily achieved once an appropriate
5 DNA sequence corresponding to the polypeptide is available. In a particular embodiment, polypeptides may be recombinantly produced as fusion polypeptides (*i.e.*, a polypeptide fused through its N- or C- terminal end to any other polypeptide (hereinafter referred to as a peptide tail), using appropriate expression vectors, such as the pMal-c2 or pMal-p2 systems of New England Biolabs in which the peptide tail is a maltose
10 binding protein, or the His-Tag system available from Novagen.

An immunogenic compound, *e.g.*, a polypeptide physically present in a composition of the invention is advantageously present in a substantially purified form, *i.e.*, it is separated from the environment in which it naturally occurs and/or is free of the
15 majority of the polypeptides that are present in the environment in which it was synthesized.

As mentioned above, the immunogenic compound may also be a DNA plasmid unable to replicate in eucaryotic cells, comprising a DNA sequence encoding a peptide
20 or a polypeptide, this latter being defined as herein above, under the control of an appropriate promoter which allows the peptide or polypeptide to be expressed in eucaryotic cells after transfection by the recombinant plasmid. As a matter of example, the CMV (Cytomegalovirus) early promoter is broadly used for the expression of a heterologous peptide or polypeptide in human cells transfected with DNA plasmid
25 encoding peptide or polypeptide.

In a particular embodiment of the present invention, a DNA plasmid advantageously encodes a peptide comprising one or several epitopes characteristic of a viral, bacterial, parasitic, or tumor-associated polypeptide. As a matter of example, it is
30 well known that tumor-associated antigens, such as Her-2 neu, are often poor immunogens, because they are essentially "self" antigens. To overcome the lack of immunogenicity, it is commonly proposed to use as an immunogenic compound, instead of DNA encoding the whole polypeptide, a DNA encoding "subdominant" epitopes

selected from the polypeptide. This strategy is also applicable to infectious microorganisms, such as HIV, *Mycobacterium tuberculosis* or *Plasmodium falciparum* for which the protective antigens are not yet defined. In a particular embodiment of the invention, aimed at the induction or the enhancement of a specific CTL response in a variety of Major Histocompatibility Complex (MHC) contexts, a pharmaceutical composition comprising a poxvirus mixed together with a DNA plasmid encoding customized peptides, may be useful. A customized peptide comprises or mimics an epitope selected throughout the whole amino acid sequence of an antigen of a pathogenic micro-organism or a tumor, as containing putative anchor motifs needed for binding to various MHC class I molecules (such as in humans, HLA-A1, HLA-A2, HLA-B7,...). The customized peptides encoded by the plasmid may all together preferably trigger a specific CTL response in the main MHC contexts of a given vertebrate.

For use in the present invention, the poxvirus may be any virus belonging to the poxviridae family. Accordingly, useful poxviruses include, capripoxvirus, suipoxvirus, molluscipoxvirus, yatapoxvirus, entomopoxvirus, orthopoxvirus and avipoxvirus; these two latter being preferred. A typical orthopoxvirus is a vaccinia virus. A suitable vaccinia virus may be *e.g.*, the highly attenuated Copenhagen strain or the NYVAC vector that is derived from the Copenhagen strain by precise deletion of 18 open reading frames (ORFs) from the viral genome as described in Tartaglia et al, Virology (1992) 188: 217. A typical avipoxvirus is a canarypoxvirus or a fowl poxvirus. A suitable canarypoxvirus may be *e.g.*, the ALVAC vector obtained as described in Tartaglia et al (*supra*). A suitable fowlpox vector may be *e.g.*, the TROVAC vector which is a plaque-cloned isolate derived from the FP-1 vaccine strain licensed for vaccination of 1 day old chicken (sold by Merial, Lyon, France) and described in Taylor et al, Vaccine (1988) 6: 497.

A poxvirus for use in the present invention may be a live, attenuated or inactivated virus. By "live virus" is meant a virus that is fully capable to reproduce its natural infectious cycle into sensitive cells, comprising virus entry, uncoating, gene expression, DNA replication, virus assembly, maturation and release. In a particular embodiment, a live virus may be attenuated. Attenuated virus may be obtained, *e.g.*, by selection of spontaneous mutants after repeated infectious cycles into sensitive cells, by

selective pressure or deletion of non-essential genes using molecular biology tools. Nevertheless, whatever the process of attenuation, the viruses that are issued remain able to reproduce themselves into sensitive cells even if sometimes the spectrum of sensitive cells can decrease. As a matter of example, it may be useful to delete the vaccinia virus genome from K3L or E3L genes to render it more sensitive to the action of interferons and consequently to reduce its host restriction range (Beattie E and al., (1996) Virus Genes, 12, 89-94). As a matter of example a suitable live virus for use in humans may be a canarypoxvirus, since in human cells such a virus exhibits an abortive infectious cycle. Additionally a suitable attenuated virus for use in humans may be a NYVAC vector. By "inactivated virus" is meant a virus that is no more capable to reproduce its entire infectious cycle into sensitive cells as a result of either a mechanical, chemical or physical treatment. As may be easily understood, inactivation is particularly advantageous when a non-recombinant poxvirus is used.

For use in the present invention, a poxvirus may be recombinant or not. A non-recombinant poxvirus does not encode any heterologous polypeptide. On the other hand, a recombinant virus is typically a virus in the genome of which is inserted one or several foreign genes (*e.g.* an heterologous coding sequence located in the genome under the control of a viral promoter allowing at least a transient expression in the virus-infected cells).

A useful recombinant poxvirus encodes a heterologous peptide or polypeptide that may be of any kind. In one embodiment of the invention, the peptide or the polypeptide may be a cytokine, such as interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18) and granulocyte macrophage-colony stimulating factor (GM-CSF); a chemokine, such as RANTES (Regulated on Activation Normal T-cell Expressed and Secreted) and MCP1 (Monocyte Chemotactic protein 1); a co-immunostimulatory molecule, such as B7, CD40, CD40L and ICAMs (inter cellular adhesion molecules); an adhesion molecule; an apoptotic factor, such as p53 and TNF (tumor necrosis factor); or an hormone such as a growth hormone.

In another embodiment, the immunogenic compound for use in the present invention is a peptide or a polypeptide and the admixed poxvirus encodes a heterologous peptide or polypeptide that cross-reacts with the immunogenic compound. Accordingly, the invention also features the use of a poxvirus for the manufacture of a pharmaceutical composition comprising a first polypeptide; wherein the poxvirus encodes a second polypeptide which immunologically cross reacts with the first polypeptide. The encoded polypeptide may be the same as the one present in the composition. In other words, the encoded polypeptide has an amino acid sequence identical to that of the polypeptide present in the composition. Alternatively, the poxvirus may encode an immunogenic polypeptide that is similar to the polypeptide present in the composition, although slightly different at the amino acid sequence level. In a particular embodiment, the immunogenic polypeptide present as such in the composition originates from a particular pathogenic strain and the poxvirus vector accompanying the polypeptide encodes an allelic variant thereof *i.e.*, the same polypeptide but from another strain. As a result, the polypeptide physically present and the encoded polypeptide may have amino acid sequences slightly different, being at least 70, 80, 90 % or more identical. A composition comprising the HIV MN gp120 together with a poxvirus encoding HIV LAI gp120 is cited as a matter of example. In another embodiment, the sequences of both the polypeptide physically present and the encoded polypeptide may derive from each other by addition, deletion or substitution of one or several amino acids, provided that these polypeptides are immunologically cross-reactive. As a matter of example, it is cited a composition comprising:

- (i) HIV gp160 and a poxvirus encoding HIV gp120;
- (ii) HIV gp160 in a soluble and non-cleavable form and a poxvirus encoding wild-type gp160;
- (iii) HIV gag p55 and a poxvirus encoding gag p18; or
- (iv) HIV gp120 and a poxvirus encoding HIV gp120-p18 hybrid protein; or
- (v) HIV gp120, HIV p18 and a poxvirus encoding HIV gp120-p18 hybrid protein.

As illustrated in section (v) hereinabove, a composition of the invention may comprise not only one but also two or more polypeptides present as such. The poxvirus may also encode several immunogenic polypeptides, at least one being immunologically cross-reactive with a polypeptide physically present in the composition; or the

composition may contain several poxviruses. Advantageously, when several polypeptides are present as such, the compositions of the invention further contain a poxvirus that operatively encodes polypeptides, each of them being two-by-two cross-reactive with the polypeptides physically present. Alternatively, the composition may
5 contain several poxviruses, each of them encoding a polypeptide cross-reactive with a polypeptide physically present. As understood by a man skilled in the art, a large variety of combinations are possible.

Recombinant pox vectors may be constructed using the basic two-step technique of
10 Piccini et al, (1987) in "Meth. In Enzymology" Acad. Press, San Diego and widely used for any pox vector as described in U.S. Patents Nos 4,769,330, 4,772,848, 4,603,112, 5,100,587 and 5,179,993. First, the heterologous DNA sequence to be inserted into the poxvirus is placed under the control of a suitable poxvirus promoter able to direct expression of the sequence in avian or mammalian cells. The expression cassette is then
15 introduced into an *E. coli* plasmid that contains a DNA region homologous to a non-essential locus of the pox vector DNA. The expression cassette is positioned so that it is flanked on both ends by poxvirus homologous DNA sequences. The resulting plasmid is then amplified by growth within *E. coli* and isolated. Second, the isolated plasmid containing the expression cassette to be inserted is transfected into a cell culture, e.g.
20 chick embryo fibroblasts, along with the poxvirus. Recombination between homologous poxvirus DNA present on the plasmid and the viral genome gives a recombinant poxvirus modified by the presence, in a non-essential region of its genome, of the expression cassette containing the heterologous DNA sequence.

25 For use in the present invention, poxviruses, irrespective of whether they are recombinant or not, may be propagated on mammalian cells such as Vero cells, BHK21 cells and Chick Embryo Fibroblasts (CEF), as described in e.g., Piccini et al, and Taylor et al (supra). Once propagated, the viral particles may be merely harvested and clarified by centrifugation. They may also be purified further according to Joklick et al, Virology
30 (1962) 18: 9.

Compositions and/or methods of the invention are useful for both therapeutic and prophylactic purposes. When the immunogenic compound is characteristic of a

pathogenic microorganism or a T.A.A., the specific immune response induced upon administration of the compositions or resulting from the methods of the invention, is advantageously protective against the pathogenic microorganism or the tumoral disorder. As a matter of example, there is a need to improve the current influenza vaccine which is not optimally protective in old people. Such pharmaceutical compositions or methods of the invention provide for improved protection over the flu vaccine of the prior art as exemplified in example 6.

Compositions of the invention can be manufactured in a conventional manner. In particular, the compounds can be formulated with a pharmaceutically acceptable diluent or carrier *e.g.*, water or a saline solution such as phosphate buffer saline. In general, a diluent or carrier can be selected on the basis of the mode and route of administration, and standard pharmaceutical practice. Suitable pharmaceutical diluents or carriers as well as pharmaceutical necessities for their use in pharmaceutical formulations are described in *Remington's Pharmaceutical Sciences*, a standard reference text in this field.

A composition of the invention may be administered to any kind of vertebrate, *i.a.* to mammals or birds, in particular to humans. To this end, one can use any conventional route in use in the vaccine field *e.g.*, via parenteral routes such as the intravenous, intradermal, intramuscular and sub-cutaneous route or mucosal routes such as nasal or oral routes. Especially, for the immunotherapy of cancer it may be useful to administer the pharmaceutical composition intratumorally or into the neighbor lymph nodes.

Compositions comprising a DNA plasmid as immunogenic compound, may advantageously be administered into the epidermis using a special device such as a gene gun or an equivalent device, or by intramuscular route. Taking into account that most of poxvirus are able to infect epidermis cells, it is worth noticing that the composition of the invention and advantageously a composition comprising a DNA plasmid mixed with a poxvirus is suitable for an intradermal or trancutaneous immunization as described by Glenn GM et al, (1998), J. Immunol. 161: 3211-3214.

In a general manner, the administration can be achieved in a single dose or repeated at intervals, *e.g.* repeated twice or more, one or two months apart.

In compositions of the invention, the appropriate dosage of the poxvirus, and the immunogenic compound depends on various parameters understood by skilled artisans such as the vector and the immunogenic compound themselves, the route of administration, the general status of the vertebrate to be vaccinated (weight, age and the like), the type of immune response that is desired and the tumoral or infectious site. An efficient amount of the compounds is such that upon administration, an immune response against the compounds will be induced. For guidance, it is however indicated that the infectious titer (amount of virus able to infect 50 % of a cell culture) per dose of the poxvirus may suitably range from 10^3 to 10^9 , preferably from 10^5 to 10^8 CCID₅₀ (Cell Culture Infectious Dose 50). The polypeptide(s) physically present in the composition may amount from 10 µg to 1 mg, advantageously from 25 to 500 µg, preferably from 50 to 200 µg ; most preferably, a single dose contains about 50-100 µg of polypeptide(s). Whenever a DNA plasmid is the immunogenic compound, a convenient dose of DNA plasmid administered may amount from several ng to a few mg depending on the size of the animal giving the composition. In human beings the suitable dose of DNA plasmid per immunization may range from 20µg to 2500µg as mentioned by Wang R et al (1998), Science, 282, 476-480

All the documents cited throughout the specification are incorporated by reference.

The invention is further explained and illustrated in the examples by reference to the figures described as follows.

Figures 1a and 1b refer to Example 1 and show mean gp160 MN/LAI ELISA antibody titers (log) in guinea-pigs immunized twice by intramuscular route (on days 1 and 29) with vCP205 and/or gp160 MN/LAI 4 µg (1a) or 40 µg (1b).

Figures 2a and 2b refer to Example 1 and show mean V3 MN ELISA antibody titers (log) in guinea-pigs immunized twice by intramuscular route (on days 1 and 29) with vCP205 and/or gp160 MN/LAI 4 µg (2a) or 40 µg (2b).

In Figures 1a and 2a : ○ corresponds to group #1 (D1 and D29 : gp160) ; ● corresponds to group #3 (D1 : vCP205 and D29 : gp160) ; ∇ corresponds to group #5 (D1 and D29 : vCP205 + gp160) ; and ▼ corresponds to group #7 (D1 and D29 : vCP205).

5

In Figures 1b and 2b : ○ corresponds to group #2 (D1 and D29 : gp160) ; ● corresponds to group #4 (D1 : vCP205 and D29 : gp160) ; ∇ corresponds to group #6 (D1 and D29 : vCP205 + gp160) ; and ▼ corresponds to group #7 (D1 and D29 : vCP205).

- 10 Figure 3 refers to Example 2 and shows CPpp antibody titers (log/ml) in guinea-pigs inoculated twice intramuscularly with various doses of vCP205. ● corresponds to group #3 ($10^{4.8}$ CCID50) ; ▼ corresponds to group #5 ($10^{5.8}$ CCID50) ; and ■ corresponds to group #8 ($10^{6.1}$ CCID50).

- 15 Figures 4a and 4b refer to Example 2 and show gp160 MN/LAI ELISA antibody titers (log/ml) in guinea-pigs inoculated twice intramuscularly with various doses of vCP205 and/or gp160 MN/LAI.

- 20 In Figure 4a, ● corresponds to group #1 (40 µg of gp160), ▼ corresponds to group #2 (80 µg of gp160) ; ■ corresponds to group #4 ($10^{4.8}$ CCID50 of vCP205 + 40 µg of gp160) ; ▲ corresponds to group #6 ($10^{5.8}$ CCID50 of vCP205 + 40 µg of gp160 mixed together) ; and ◆ corresponds to group #7 ($10^{5.8}$ CCID50 of vCP205 + 40 µg of gp160 injected separately).

- 25 In Figure 4b, ○ corresponds to group #3 ($10^{4.8}$ CCID50 of vCP205), ∇ corresponds to group #5 ($10^{5.8}$ CCID50 of vCP205), □ corresponds to group #8 ($10^{6.1}$ CCID50 of vCP205), ■ corresponds to group #4 ($10^{4.8}$ CCID50 of vCP205 + 40 µg of gp160), ▲ corresponds to group #6 ($10^{5.8}$ CCID50 of vCP205 + 40 µg of gp160 mixed together), ◆ corresponds to group #7 ($10^{5.8}$ CCID50 of vCP205 + 40 µg of gp160 injected separately).
- 30

Figures 5 to 8 refer to Example 3 and show the mean ELISA antibody titers (log/ml) in macaques immunized intramuscularly with $10^{6.5}$ CCID50 vCP205 and/or 100 µg gp160

MN/LAI adjuvanted or not (Figure 5 : gp160 ELISA antibody ; Figure 6 : V3 MN ELISA antibody ; Figure 7 : p24 LAI ELISA antibody ; Figure 8: CPpp ELISA antibody). ♦ corresponds to group #1 ; ∇ corresponds to group #2 ; ○ corresponds to group #3 ; and ▼ corresponds to group #4. (■ is irrelevant).

5

Figure 9 refers to Example 3 and shows the HIV MN seroneutralizing antibody titers (log) in macaques immunized five times intramuscularly with $10^{6.5}$ CCID50 vCP205 and/or 100 µg gp160 MN/LAI adjuvanted or not at weeks 0 (square-dotted box), 16 (hatched box) and 26 dotted box). Schemes A to D correspond respectively to groups #1 to #4.

10

Figures 10a and 10b refer to Example 4 and show ELISA CPpp antibody (1a) and gp160 MN/LAI antibody (1b) mean titers in guinea-pigs primed intramuscularly with a mixture of gp160 MN/LAI (5µg) and different doses of crude or purified CPpp, then boosted with 5 µg of gp160 MN/LAI. ○ corresponds to group #1 ; ● corresponds to group #2 ; ∇ corresponds to group #3 ; ▼ corresponds to group #4 ; and □ corresponds to group #5.

15

Figures 11a and 11b refer to Example 5 and show ELISA IgG CPpp antibody (2a) and gp160 MN/LAI antibody (2b) mean titers in guinea-pigs primed intramuscularly with a mixture of gp160 MN/LAI (5 µg) and different fractions of ALVAC-Luc (vCP297), either inactivated or not, then boosted (week 4) with 5 µg of gp160 MN/LAI. ○ corresponds to group #1 ; ● corresponds to group #2 ; ∇ corresponds to group #3 ; ▼ corresponds to group #4 ; and □ corresponds to group #5.

20

Figures 12 and 13 refer to example 6 and show respectively the IgG1 and IgG2a ELISA antibody titers specific for A/Texas in each individual aged DBA/2 mice immunized twice with either 3µg of A/Texas (group 1), 2×10^7 CCID50 of CPpp and 3µg of A/Texas (group 2) or 2×10^7 CCID50 of CPpp (group 3). ■ and ♦ correspond to mice of group 1 respectively after one and two immunizations. ▲ and □ correspond to mice of group 2 respectively after one and two immunizations. ◆ and ◇ correspond to mice of group 3 respectively after one and two immunizations.

25

30

Figure 14 refers to example 6 and shows the survival curves of the 3 immunized groups after a lethal challenge with A/Taiwan. Δ corresponds to group 1; \square corresponds to group 2; \blacklozenge corresponds to group 3.

- 5 Figure 15 refers to example 6 and shows the morbidity curves of the 3 immunized groups after a lethal challenge with A/Taiwan. Δ corresponds to group 1; \square corresponds to group 2; \blacklozenge corresponds to group 3.

10

15 Example 1: Simultaneous immunization with ALVAC-HIV (vCP205) and gp160 MN/LAI in guinea pigs

1A - vCP205 preparation

- 20 vCP205, an ALVAC pox vector capable of expressing HIV proteins, is described in Example 14 of WO 95/27507. Briefly, it contains a first heterologous sequence encoding the env gp120 MN + the transmembrane region of LAI gp41, and a second sequence encoding LAI (gag + protease); these sequences are inserted in the C3 locus and placed under the control of promoters H6 and I3L.

25

Clarified vCP205 was produced on chick embryo fibroblasts in DMEM - Ham F12 medium without serum, harvested in lactoglutamate and clarified by centrifugation.

The preparation used hereinafter has a mean titer of $10^{8.5}$ CCID₅₀ / ml on QT35 cells.

- 30 Purified vCP205 was produced as described above and further purified according to Joklick et al, (supra). The vCP205 preparation in phosphate buffer saline (PBS) 20 mM pH 7.2 (in the absence of Mg^{++} and Ca^{++}) as used hereinafter, has a mean titer of $10^{8.8}$ CCID₅₀ / ml on QT35 cells.

1B - gp160 MN/LAI preparation

A recombinant vaccinia virus vector, VVTG9150, is used for gp160 production.
5 VVTG9150 operatively encodes a hybrid, soluble HIV-1 gp160 in which the gp120 moiety derives from HIV-1 MN and the gp41 trans-membrane part comes from the LAI isolate. The DNA sequences corresponding to these two compounds are fused together using an artificial *SmaI* restriction site, which modifies neither the gp120, nor the gp41 amino acid sequence. The construction of the two partners is briefly described as
10 follows.

The sequence encoding the MN gp120 was amplified from cells SupT1 infected with HIV- MN, using the PCR technique with oligonucleotides which introduce a *SphI* and *SmaI* restriction sites respectively located immediately downstream of the sequence
15 encoding the leader peptide and upstream of the cleavage sites located between gp120 and gp41.

The sequence encoding the LAI gp41 was produced as follows: The complete HIV-1 LAI env coding sequence was placed under the control of the vaccinia pH5R promoter.
20 Several modifications were introduced into this encoding sequence. First a *SphI* restriction site was created immediately downstream of the sequence encoding the leader peptide, without altering the amino acid sequence. Second, a *SmaI* restriction site was created immediately upstream of the sequence encoding the cleavage sites between gp120 and gp41, without altering the amino acid sequence. Third, the two cleavage sites
25 in position 507 – 516 (amino acids numbered according to Myers et al, In: Human retroviruses and AIDS (1994) Los Alamos National Lab. (USA)) were mutated (original sequence KRR ... REKR mutated into QNH ... QEHN). Fourth, the sequence encoding the transmembrane hydrophobic peptide IFIMIVGGLVGLRIVFAVLSIV (amino acids 689 – 710 in Myers et al (supra)) was deleted. Fifth, a stop codon was substituted for the
30 second E codon of the sequence encoding PEGIEE (amino acids 735 – 740 in Myers et al (supra)) i.e., the 29th amino acid of the intracytoplasmic domain.

The plasmid, in which the LAI sequence was inserted between vaccinia virus thymidine kinase (TK) gene homologous regions, was cut with *SphI* and *SmaI* and further ligated with the MN gp120 sequence. VVTG9150 was then constructed by conventional homologous recombination and propagated for MN/LAI gp160 expression according to the conventional method used for vCP205 on BHK21 cells. The protein was purified by immunoaffinity chromatography.

1C - Experimental procedure

10 Guinea pigs were submitted to immunization protocols as described in Table 1 hereinafter.

Table 1

Group # (Guinea-pig)	Inoculation days	
	D1	D29
1 (1, 2, 3, 4, 5)	4 µg gp160	4 µg gp160
2 (6, 7, 8, 9, 10)	40 µg gp160	40 µg gp160
3 (11, 12, 13, 14, 15)	10 ^{6.1} CCID50 ALVAC-HIV	4 µg gp160
4 (16, 17, 18, 19, 20)	10 ^{6.1} CCID50 ALVAC-HIV	40 µg gp160
5 (21, 22, 23, 24, 25)	10 ^{6.1} CCID50 ALVAC-HIV + 4 µg gp160	10 ^{6.1} CCID50 ALVAC-HIV + 4 µg gp160
6 (26, 27, 28, 29, 30)	10 ^{6.1} CCID50 ALVAC-HIV + 40 µg gp160	10 ^{6.1} CCID50 ALVAC-HIV + 40 µg gp160
7 (31, 32, 33, 34, 35)	10 ^{6.1} CCID50 ALVAC-HIV	10 ^{6.1} CCID50 ALVAC-HIV

Each dose was administered intramuscularly under a final volume of 1.2 ml (0.6 ml in each thigh). When vCP205 and gp160 were both administered, these two products were mixed together before.

20 Serological analyses were carried out with blood samples collected on days 0 (one day before the first immunization), 28, 43 and 57. Antibodies to HIV gp160 glycoprotein and V3 peptide were titrated by ELISA as follows:

Maxisorp F96 NUNC plates were coated for 1 hour at 37°C, then overnight at 4°C, with one of the following antigens, diluted in 0.1 M carbonate buffer, pH 9.6: 130 ng per well of purified gp160 MN/LAI; 200 ng of V3 peptide from HIV MN.

5

Plates were then blocked for 1 hour at 37°C with 150 µl of phosphate buffered saline (PBS) pH 7.1 - 0.1 % Tween 20 - 5 % (w/v) powdered skim milk, (PBS-Tween-milk). All next incubations were carried out in a final volume of 100 µl, followed by 3 or 4 washings with PBS, pH 7.1 - 0.1 % Tween 20.

10

Serial threefold dilutions of the sera, ranging from 1/100 to 1/24300 or 1/1000 to 1/243000, in PBS-Tween-milk, were added to the wells and incubated for 90 min at 37°C. After washings (3 times), anti-guinea-pig IgG peroxylase conjugate (Sigma, rabbit IgG fraction) was diluted at 1/3000 in PBS-Tween-milk, added to the plates and incubated for another 90 min at 37°C. The plates were further washed (4 times) and incubated in the dark for 30 min at room temperature with O-phenylenediamine dihydrochloride (Sigma) at 1.5 mg/ml in 0.05 M phosphate citrate buffer, pH 5.0 containing 0.03 % sodium perborate (Sigma). The reactions were stopped with 50 µl of 4N H₂SO₄.

20

The optical density (OD) was measured at 490-650 nm with an automatic plate reader (Vmax, Molecular Devices). The blanks (mean value) were subtracted to the data and duplicate values averaged. The antibody titers were calculated for the OD value range of 0.2 to 1.3, from the regression curve of a standard hyperimmune guinea-pig serum specific for both gp160 and V3 antigens, present on each ELISA plate.

25

The titer of the standard serum had been previously determined according to the formula:

$$\text{Titer} = \log \frac{\text{OD}_{490-650} \times 10 (\text{OD value range: 0.2 to 1.3})}{1 / \text{dilution}}$$

30

1D - Serological results

Averaged titers for each group of guinea pigs are presented in Figures 1 (gp160 antibody titers) and 2 (V3 antibody titers).

Comparison of the anti-HIV antibody responses induced by gp160 alone (groups #1 and #2), vCP205 alone (group #7), and combination of both antigens (groups #5 and #6)

Antibody responses to gp160

The lowest responses were observed, after both the primary and booster immunizations, in guinea pigs that received 4 µg of gp160 (group #1). With 40 µg of gp160 (group #2), humoral responses were much more elevated: only one inoculation was required for all animals to seroconvert, *versus* two with the 4 µg dose ; and the mean antibody titers to V3 and gp160 were higher in group #2 than in group #1 (> +1 log higher on week 6).

vCP205 ($10^{6.1}$ CCID₅₀) injected alone (group #7) elicited anti-HIV antibodies at comparable but lower levels than those induced by gp160 alone at 40 µg, especially after the booster injection (difference in mean titers \approx -0.4 log on week 6).

Mixing vCP205 with 4 µg of gp160 (group #5) was not found to significantly enhance the antibody response comparatively to vCP205 alone. Conversely, and of great interest, two immunizations with the combination vCP205 plus gp160 at 40 µg (group #6) induced the best antibody titers, higher than those raised by vCP205 alone (group #7) (raise of mean ELISA titers \approx +0.8 log on week 6) and, in lesser extent, by 40 µg of gp160 alone (group #2) (\approx +0.4 log on week 6).

Antibody responses to V3

Although the antibody titers raised against the V3 domain were, as previously observed, lower than those induced against whole gp160, the reactivity pattern to V3 was similar to that obtained to gp160. In particular, the (vCP205 plus 40 µg of gp160) combination proved to be the best immunogen, whereas the 4 µg dose of gp160 injected alone was the worst.

Comparison of the anti-HIV antibody responses induced by the mixture of vCP205 plus gp160 (groups #5 and #6) and by a prime (vCP205) / boost (gp160) immunization regimen (groups #3 and #4)

- 5 As observed in previous tests, a clear priming effect of vCP205 on the anti-HIV humoral responses following a boost with gp160 (at either 4 or 40 µg) was found. Nonetheless, animals immunized according to this prime/boost regimen displayed lower responses to V3 than those inoculated with two injections of the mixture vCP205 plus gp160 (using 4 or 40 µg of gp160). Similar differences were seen when anti-gp160 responses were
10 considered, but only with 40 µg of gp160.

Noticeably, the prime/boost immunization using: (i) 40 µg of gp160 (group #4) gave antibody levels equivalent to those elicited by two inoculations of gp160 alone at 40 µg (group #2); or (ii) 4 µg of GP160 (group #3) raised antibody titers similar to or lower
15 than those induced by two injections of vCP205 (group #7).

General conclusion

Immunogenicity of the different combinations of ALVAC-HIV vCP205 and/or gp160
20 MN/LAI evaluated in the present study in guinea pigs can be classified as followed:

$$\text{gp160 (4 µg)} < \text{prime vCP205 / boost gp160 (4 µg)} = \text{vCP205} = \text{vCP205 + gp160 (4 µg)}$$
$$= \text{prime vCP205 / boost gp160 (40 µg)} = \text{gp160 (40 µg)} < \text{vCP205 + gp160 (40 µg)}.$$

- 25 In particular, these results revealed that two co-injections of vCP205 and gp160 can induce higher anti-HIV serological responses (to V3 and gp160) than two inoculations of either vCP205 or gp160 alone, or than a prime (vCP205) / boost (gp160) immunization. Such an enhancing effect was observed mainly when vCP205 was combined with a high dose of gp160 (40 µg) but not with a lower one (4 µg).

- 22 -

Example 2: Analysis of the enhancing effect of a mixture vCP205 + gp160 MN/LAI on the antibody response to gp160 MN/LAI in guinea-pigs

The experiment reported in Example 2 were performed in guinea-pigs (i) to confirm the ability of the mixture gp160 MN/LAI plus vCP205 to stimulate the antibody response to gp160, as previously observed in Example 1; (ii) to determine whether this enhancement results from a simple additive or rather a synergistic effect between the two immunogens; and (iii) to evaluate whether such an effect can be obtained when the two products are inoculated simultaneously at distinct sites or only when they are mixed.

2A - vCP205 preparation was achieved as described in Example 1A hereinabove

2B - gp160 preparation was achieved as described in Example 1B hereinabove

2C - Experimental procedures

Thirty-nine guinea pigs distributed in eight groups received vCP205 and/or gp160 doses as stated in Table 2.

Table 2

		ALVAC-HIV (vCP205) (CCID50)				
		0	$10^{4.8}$	$10^{5.8}$		$10^{6.1}$
gp160 (μ g)	0		# 11 to 14	# 21 to 24		# 36 to 40
	40	# 1 to 5	mixed # 15 to 19	mixed # 25 to 30	separately # 31 to 35	
	80	# 6 to 10				

Each guinea pig received intramuscularly two identical injections (each under a volume of 1.2 ml), one month apart. The viral vector and the mixtures were administered in both thighs, whereas gp160 alone was administered in the right fore leg.

Serological analyses were carried out with blood samples collected on days 1, 15, 28, 43 and 57. Antibodies to HIV gp160 MN/LAI glycoprotein and to non-recombinant purified canary pox (CPpp) were titrated by ELISA as described in Example 1C. To this end, 500

ng of CPpp / well were used as well as a standard hyperimmune guinea-pig serum for CPpp.

2D - Serological results

5

Anti-CPpp antibody response

The antibody response elicited against CPpp was measured in the three groups of guinea pigs inoculated with $10^{4.8}$, $10^{5.8}$ or $10^{6.1}$ CCID50 of ALVAC-HIV (vCP205) alone (groups #3, #5 and #8, respectively). The mean titers of each group are presented in Figure 3.

The doses of $10^{4.8}$ and $10^{5.8}$ CCID50 of vCP205 raised similar anti-CPpp antibody levels, which proved to be lower than those induced by the dose of $10^{6.1}$ CCID50 of ALVAC-HIV, mostly after the first injection (difference in mean titers of ~ -0.7 log on week 4).

Anti-gp160 MN/LAI antibody response

20 The antibody response to gp160 MN/LAI was measured in all immunized animals. The mean titers of each group are represented in Figures 4a and 4b.

When the groups of guinea pigs were globally compared by variance analysis, a significant difference between immunogens was observed in the antibody response elicited against gp160 ($p < 0.0005$).

30 Injections of either gp160 MN/LAI at 40 or 80 μ g (groups #1 and #2) or ALVAC-HIV (vCP205) at $10^{5.8}$ or $10^{6.1}$ CCID50 (groups #5 and #8) were found to induce close anti-gp160 antibody levels which proved to be statistically identical along the study. ALVAC-HIV (vCP205) at the dose of $10^{4.8}$ CCID50 (group #3) appeared to raise lower antibody responses, the difference in mean titers with groups #1, #2, #5 and #8 ranging from -0.4 to 1.8 log during the serology, but statistical significance was evidenced only with group #8.

These results suggested that the gp160-specific humoral response elicited by the HIV protein at 40 to 80 µg or the recombinant ALVAC-HIV (vCP205) at $10^{5.8}$ or $10^{6.1}$ CCID50 had reached its maximum. However, mixture $10^{4.8}$ CCID50 vCP205 plus 40 µg gp160 (group #4) was found to induce elevated antibody titers which proved to be significantly higher than those raised (i) by vCP205 alone at $10^{4.8}$, $10^{5.8}$ or $10^{6.1}$ CCID50 (difference in mean titers ranging from +0.5 to +2.6 log), and (ii) by gp160 alone at 40 or 80 µg (difference in mean titers ranging from +0.8 to +2.5 log).

The anti-gp160 antibody levels induced by the mixture vCP205 at $10^{5.8}$ CCID50 plus 40 µg gp160 (group #6) also appeared to be high and did not significantly differ from those elicited in group #4 (mixture with vCP205 at $10^{4.8}$ CCID50). Moreover, the simultaneous injection of $10^{5.8}$ CCID50 vCP205 and 40 µg gp160 either mixed (group #6) or injected separately (group #7) gave similar increased antibody responses, as confirmed statistically.

Whether or not the strongest anti-gp160 antibody responses observed with the three combinations of vCP205 and gp160 (groups #4, #6 and #7) resulted from a simple additive or rather a synergistic effect between both immunogens was difficult to assess. In an attempt to address this issue, the mean ELISA titers measured experimentally for each combination were compared to the estimated titers that would result from an additive effect between gp160 and vCP205. As shown in Table 4, the titers measured for the mixture with vCP205 at $10^{4.8}$ CCID50 (group #4) were found to be higher than the theoretical additive titers, the ratio "measured titer / theoretical additive titer" ranging from 5.4 to 165.5 along the serology. This ratio was also above 1 albeit never exceeding 10, for the group receiving the mixture with vCP205 at $10^{5.8}$ CCID50 (group #6). This was also true when gp160 was administered separately to vCP205 at the same dose (group #7), but only after the primo immunization (weeks 2 and 4).

These results suggested that a synergism between ALVAC-HIV (vCP205) and gp160, potentiating the antibody response to gp160, can occur. Such an effect would also take place when both immunogens are injected separately, although apparently less efficiently.

General conclusion

- The ability of the combination of gp160 MN/LAI (40 µg) and ALVAC-HIV (vCP205) ($10^{4.8}$ or $10^{5.8}$ CCID₅₀) to stimulate the humoral response to gp160 MN/LAI in guinea
- 5 pigs was confirmed. The antibody levels elicited against the HIV protein by these mixtures were indeed increased comparatively to those obtained by each immunogen at either a similar or a two-fold (or more) higher dose (*i.e.* gp160 at 40 or 80 µg or ALVAC-HIV at $10^{4.8}$, $10^{5.8}$ or $10^{6.1}$ CCID₅₀).
- 10 This stimulating effect seemed to result from a synergistic rather than an additive phenomenon, and could also occur at distance when both antigens were injected at distinct sites.

- Example 3: Comparison of the immune response induced in rhesus macaques either
- 15 by a mixture of vCP205 + gp160 MN/LAI or a prime boost immunization
vCP205 / gp160 MN/LAI in aluminum hydroxide Al (OH)₃ (Alum)

- 3A - vCP205 preparation was achieved as described in Example 1A hereinabove
- 20 3B - gp160 preparation was achieved as described in Example 1B hereinabove
- 3C - Experimental procedure

- Thirteen rhesus macaques (*Macaca mulatta*) were immunized according to the
- 25 immunization protocols as shown in Table 3.

30

35

Table 3

Macaques		Immunizations (Weeks)				
Group #	Sex and number	W0	W4	W8	W12	W24
1	F1, F2	gp160	gp160	gp160	gp160	gp160
2	F4, F5, M6	gp160 + alum	gp160 + alum	gp160 + alum	gp160 + alum	gp160 + alum
3	M11, F12, M13, F18	ALVAC-HIV + gp160	ALVAC-HIV + gp160	ALVAC-HIV + gp160	ALVAC-HIV + gp160	ALVAC-HIV + gp160
4	F19, F20, F21, M22	ALVAC-HIV	ALVAC-HIV	gp160 + alum	gp160 + alum	gp160 + alum

F: female; M: male.

- 5 Macaques were administered doses intramuscularly in one thigh (right or left alternatively), under a final volume of 1 ml, comprising $10^{6.5}$ CCID₅₀ vCP205, 100 µg gp160 and/or 0.3 mg alum.

10 Blood samples were collected every two weeks, starting on week 0 (first immunization week).

Antibodies to HIV gp160 MN/LAI glycoprotein, V3 MN peptide, p24 LAI and CPpp were titrated by ELISA (Figures 5 to 8) as described in Example 1C. Reagent dosages were as follows: gp160 MN/LAI: 130 ng / well; V3 MN peptide: 200 ng / well; p24 LAI: 130 ng / well; and CPpp: 500 ng / well.

Two different peroxylase conjugates were used, diluted in PBS-Tween-milk, depending on the coating antigen:

- for the gp160 MN/LAI, V3 MN and p24 LAI titrations: goat anti-monkey IgG peroxylase conjugate (Cappel, ref. 55432) at 1/1,000
- for the CPpp titrations: sheep anti-human Ig peroxylase conjugate (Amersham, ref. NA 933) at 1/300.

Antibody titers were calculated for the OD value range of 0.2 to 1.3, from the regression curve of a standard specific hyperimmune macaque serum present on each ELISA plate.

Neutralizing test were also carried out (Figure 9). The assay determines the dilution of
5 serum that prevents the development of syncytia in 50 % of microwells infected with 10
CCID₅₀ of HIV MN. The MN strain was obtained from F. Barré-Sinoussi and
propagated in CEM clone 166 cells.

Sera were decomplexed and twofold serial dilutions in RPMI beginning 1/10 were
10 prepared. Equal volumes of serum dilution and HIV suspension (500 µl each) were
mixed and incubated for 2 hrs at 37°C. The HIV suspension had been adjusted to contain
10² to 10^{2.5} CCID₅₀ per ml.

Prior to use, indicator CEMss cells were plated in microwells coated with poly-L-lysine,
15 and incubated for 1 hr at 37°C. Culture medium was removed and replaced with the
virus / serum mixtures (100 µl / well, 6 wells per dilution). After 1 hr incubation at
37°C, culture medium was added to each well and the plates were incubated at 37°C. All
incubations were done in a 5 % CO₂ incubator.

20 After 7 and 14 days respectively, the cultures were examined under the microscope and
wells showing syncytia were recorded. Neutralizing 50 % titer was computed according
to SPEARMAN and KÄRBER and expressed as the log₁₀ of the end-point. As a
confirmation, supernatants of the cultures were collected on day seven, pooled for each
dilution and assayed for reverse transcriptase (RT) activity.

25

Each assay included a set of uninfected microwells as negative controls, an infectivity
titration of the virus suspension and a titration of antibody in a reference serum.

3D - Serological results

30

The mean antibody kinetics are presented in Figures 5 to 9.

gp160 MN/LAI antibodies

All animals injected with gp160 MN/LAI only (group #1) seroconverted, although weakly, to the HIV protein after one immunization and consistently increased their response after the second and third inoculations (mean titers raised by +0.8 to +1.0 log two weeks post-injection). After the fourth immunization, titers reached similar levels than after the third one, and then decreased. The last inoculation induced a strong booster effect (mean titers raised by +1.3 log two weeks post-injection) and elicited the highest titers of the period examined (5.0 log on week 26).

10

A marked adjuvant effect of alum (group #2) was observed on the anti-gp160 antibody response in naive macaques. Indeed, as compared to the non-adjuvanted group (#1), the mean ELISA titers were enhanced by +1.0 to +2.0 log after each of the four first inoculations, and to a lesser extent after the fifth injection (+0.3 to +0.5 log). The highest levels of gp160-specific antibodies were obtained earlier than in group #1. This adjuvant effect was found to be significant (statistical analysis performed when possible, *i.e.* on weeks 4, 6 and 8, using the Dunnett's t-test).

Interestingly, the mixture (ALVAC-HIV+gp160) (group #3) was found to induce a significant higher response to gp160 than ALVAC-HIV after one or two inoculation(s) (group # 4) (difference in mean titers up to +1.5 log). The anti-gp160 antibody titers were also more elevated in macaques injected with the mixture than in the vCP205-primed animals boosted with gp160 in alum (group #4). However, the differences were slight (+ 0.7 log maximum) and found to be significant only on weeks 20, 24 and 28 (group #4) (Newman-Keuls test).

The combination (ALVAC-HIV+gp160) also proved to be a better immunogen than gp160 alone (group #1) (mean titers between +0.8 to +1.7 log higher along the experiment), and did not strongly differ from gp160 adjuvanted in alum (group #2) (differences in mean titers = +/- 0.5 log).

Finally, the prime/boost immunization regimen (group #4) induced in most cases higher antibody titers than inoculation with gp160 alone (group #1), especially after the gp160

boosts (differences up to +1.4 log), but lower responses than injection with gp160 in alum (group #2), particularly after the ALVAC priming (differences up to -2.0 log).

V3 MN antibodies

5

On the whole, antibody responses elicited against V3MN shew a similar pattern than against gp160MN/LAI, although to a lesser magnitude.

Alum (group #2) also increased the antibody titers to V3MN as compared to the non-
10 adjuvanted group (#1), and this enhancing effect was found to be significant at weeks # 2, 4, 6, 8.

Animals injected with the mixture (ALVAC-HIV+gp160) (group #3) displayed significantly increased anti-V3MN responses than those receiving the prime/boost
15 immunization (group #4) but only after the first and the second priming with ALVAC-HIV (weeks 4, 6 and 8) and following the last gp160 boost (weeks 26 and 28) (Newman-Keuls test). Moreover, similarly to what was seen on gp160, and although no statistical analysis could be performed given the low number of animals tested, the mixture raised
20 V3MN responses higher than did gp160 alone (group #1) (titers augmented by +1.0 to +1.8 log), and close to those induced by gp160 adjuvanted in alum (group #2) (titers = +/- 0.5 log in most cases).

p24 LAI antibodies

25 In the group of macaques injected with the mixture (ALVAC-HIV+gp160) (#4), 2 animals out of 4 developed an antibody response against p24 LAI as compared to the preimmune samples: #11 became positive after two inoculations and titers increased by up to +1.3 log following the next immunizations; #18 clearly seroconverted after the third injection and maintained or decreased its response afterwards.

30

In group #5 receiving the prime/boost immunization, only 1 or possibly 2 from group #5 was (were) found to be positive on p24 LAI: #19 raised antibodies as soon as the first ALVAC priming; #22 was hardly positive after the last gp160 boost.

Anti-canarypox (CPpp) antibodies

All macaques immunized against ALVAC-HIV vCP205 either two (group #4) or five (group #3) times elicited CPpp-specific antibodies two weeks after the first injection and reached their maximal responses after the second inoculation (week 6). Following the gp160 boosts in group #4, the anti-CPpp titers gradually decreased and were reduced by -1.0 log on week 28. In group #3, the mean antibody levels were maintained until week 14 (two weeks after the fourth injection), diminished (-0.7 log), and then increased to their maximum after the last booster immunization (week 26).

3E - HIV-1 MN neutralizing antibody response

The mean titers of each group of macaques are presented in Figure 9.

All the tested animals developed anti-HIV-1 MN neutralizing antibodies when examined after the fourth (week 16) and the fifth (week 26) injection, as compared to the preimmune samples (week 0).

Because of the low number of macaques studied in groups #1 and #2, no statistical comparison could be performed for these animals. However, the lowest neutralizing titers were observed in group #1 inoculated with non-adjuvanted gp160. In group #2 (except for week 26), injected with gp160 adjuvanted in alum, the neutralizing response was stronger than in group #1, similar on week 16 and higher on week 26 than in group #4 (prime/boost immunization), and slightly lower than in group #3 injected with the (ALVAC-HIV+gp160) mixture.

Paired comparisons of groups #3 and #4 by the Newman-Keuls test revealed no statistical difference on week 16, but showed that the mixture (ALVAC-HIV+gp160) (group #3) induced significantly higher neutralizing titers than the prime/boost immunization (group #4) on week 26.

General conclusion

The present assay showed that the mixture vCP205 ($10^{6.5}$ CCID₅₀) plus gp160 (100 µg) elicited significantly higher gp160 and V3-specific responses than vCP205 or gp160 alone, and in some cases than the prime/boost immunization (vCP205/gp160 in alum), mainly after the final gp160 booster injection. The vCP205+gp16 mixture proved to be similarly immunogenic to gp160 adjuvanted in alum; given the low number of animals studied in the other groups. Moreover, the mixture appeared to evoke the best seroneutralizing responses to HIV-1-MN after the last fifth injection, although significance of this result could be proven only when compared with the prime/boost immunization, given the low number of animals in the other groups

Example 4: Immunogenicity of purified gp160 MN/LAI in the absence or presence of canarypox (ALVAC), in guinea-pigs

The experiment reported in the present Example 4 shows that both crude and purified non-recombinant ALVAC (CPpp) display adjuvant properties.

4A - CPpp preparations

CPpp (ALVAC) is derived from a canarypox strain isolated from a pox lesion on a infected canary, as described in Tartaglia et al, Virology (1992) 188: 217. CPpp is produced on chick embryo fibroblasts in DMEM-Ham F12, washed without serum and resuspended in lactoglutamate (crude CPpp). Instead of being resuspended in lactoglutamate, purified CPpp is obtained according to the purification process described in Joklick et al, Virology (1962) 18: 9.

4B- gp160 MN/LAI preparation

30

gp 160 preparations were achieved as descibed in example 1B

4C - Experimental procedure

Guinea pigs were submitted to immunization protocols as described in Table 4 hereinafter.

5

Table 4

Group (Guinea-pig #)	Primo-immunization (D1)			Booster (D29)
	gp160 dose (μ g)	ALVAC (CPpp)	ALVAC dose (CCID50)	gp160 dose (μ g)
1 (1,2,3,4,5)	5	None	0	5
2 (6,7,8,9,10)	5	Crude	10^6	5
3 (11,12,13,14,15)	5		10^6	5
4 (16,17,18,19,20)	5	Purified	10^7	5
5 (21,22,23,24,25)	5		10^8	5

Animals received both the primo and booster 1.10 ml doses intramuscularly (0.55 ml in each thigh) one month apart.

10

Serological analyses were carried out as described in Example 1C, using blood samples collected at days -1, 28 and 56.

15 4D- Serological analyses

Serological analyses were carried out with blood samples collected on days -1 (one day before the first immunization), 28, and 56. Antibodies to HIV gp160 glycoprotein and CPpp were titrated by ELISA using the same procedure as described in example 1C

20

4E - Serological results

Anti-CPpp antibodies (Figure 10a)

- 5 Four weeks after the first immunization, all the animals seroconverted (except group #1 which did not received any CPpp), and the titers remained stable after the gp160 booster till week 8.

Response to canarypox induced by 10^6 CCID₅₀ of crude CPpp was significantly higher
10 (+0.7 to 0.8 logs) than the one raised with the same dose of purified virus, was comparable to that elicited by 10^7 CCID₅₀ of purified CPpp, and was lower (~ -0.8 log) than that obtained with the dose of 10^8 CCID₅₀ of purified CPpp.

Anti-HIV gp160 MN/LAI antibodies (Figure 10b)

15

Anti-gp160 MN/LAI antibodies were elicited during the four weeks following the first injection in all animals, except some in group #5. In this group, which received a mixture of gp160 and 10^8 CCID₅₀ of purified CPpp, only 3 animals out of 5 seroconverted to gp160. For each guinea pig, a booster effect was noticeable after the second injection of
20 5 μ g of gp160.

The best anti-gp160 antibody responses were obtained in group #3, primed with gp160 mixed with the lowest dose (10^6 CCID₅₀) of purified CPpp. Indeed, this group displayed a significant increase in antibody titers (+0.8 and +0.9 logs at weeks 4 and 8,
25 respectively), comparatively to group #1 inoculated with the protein alone.

Co-injection of 10^7 CCID₅₀ of purified CPpp with gp160 (group #4) also enhanced the humoral response as compared to injection of the protein alone, but only on week 8 after the gp160 boost (+0.7 log). Surprisingly, in group #5 (gp160 mixed with 10^8 CCID₅₀ of
30 purified CPpp), a significant decrease in responding animals was observed (3 out of 5, versus 5 out of 5 in all other tested conditions). Moreover, the mean antibody titer (2.352 log) of the positive guinea pigs from group #5 was the lowest obtained in this assay.

Nevertheless, such a CPpp-induced inhibitory effect did not have any influence on the secondary response to gp160, which reached similar levels to those obtained in group #1.

Noticeably, addition of 10^6 CCID₅₀ of crude CPpp to gp160 did not improve the
5 antibody response as compared to gp160 alone.

General conclusion

This study clearly demonstrates an adjuvant effect of crude and purified CPpp on the
10 immunogenicity of gp160 MN/LAI inoculated IM in guinea pigs. Such a stimulation of the anti-gp160 antibody response was mostly observed at 10^6 CCID₅₀ of purified CPpp, whereas a marked inhibitory effect was noted at the higher dose of 10^8 CCID₅₀.

The results obtained with crude CPpp at 10^6 CCID₅₀ indicates that this CPpp
15 preparation does not seem to be able to enhance the anti-gp160 humoral response when combined with the 5 µg dose of the tested gp160. However, the same preparation does enhance the response to 1 µg gp160 (data not shown). Accordingly, the crude CPpp immunomodulating effect seems to be gp160-dose dependent.

20 Altogether, these findings show that both CPpp and gp160 must be used at optimal concentrations to see an adjuvant effect of canarypox. The present observation that both crude and purified CPpp can stimulate the anti-gp160 antibody response is in favor of the hypothesis that CPpp has intrinsic immuno-stimulating properties.

25 Example 5: Immunogenicity of gp160 MN/LAI in the presence of purified ALVAC-Luc (vCP292) inactivated or not, in guinea-pigs

5A - vCP297 preparation

30 vCP297 is an ALVAC vector derived from CPpp by homologous recombination so as to produce a vector in which the luciferase encoding sequence is placed under the control of an ALVAC promoter. vCP297 is produced and purified as described in Example 4A.

One ml of a vCP297 preparation exhibiting a mean titer of $10^{9.3}$ CCID50 on QT35 cells, was diluted 1/10 in PBS without Ca^{++} and Mg^{++} and inactivated at 56°C , 7 hours. It was then centrifuged during 5 hours at 10.000 rpm (centrifuge Sigman 201M) and the pellet and supernatant were harvested separately. The protein quantity and residual viral titer were quantified, being respectively 55 $\mu\text{g}/\text{ml}$ and $10^{3.5}$ CCID50/ml for the pellet and ≈ 1 $\mu\text{g}/\text{ml}$ and $10^{0.3}$ CCID50/ml for the supernatant.

5B - gp160 preparations were achieved as described in Example 1B.

10 5C - Experimental procedure

Guinea pigs were submitted to immunization protocols as described in Table 5 hereinafter.

15 Table 5

Group (Guinea-pig #)	First immunization (D1)		Booster (D29)
	gp160 MN/LAI doses (μg)	Purified ALVAC-Luc (vCP297)	gp160 MN/LAI doses (μg)
		Proteins (μg) Infectious dose (CCID50)	
1 (1, 2, 3, 4, 5)	5	0 0	5
2 (6, 7, 8, 9, 10)		0.055 10^5	
3 (11, 12, 13, 14, 15)		0.55 10^6	
4 (16, 17, 18, 19, 20)		pelleted fraction of the inactivated virus 0.55 $10^{1.5}$	
5 (21, 22, 23, 24, 25)		supernatant of the inactivated virus after centrifugation ¶ ~ 1 $= 10^{0.3}$	

Animals received the primo and booster doses under a final volume 1.10 ml, intramuscularly (0.55 ml in each thigh), one month apart.

- 5 Serological analyses were carried out as described in Example 1C, using blood samples collected at days -1, 28 and 56.

The isotypic distribution of the anti-gp160 humoral response was measured at day 56, using the procedure and conditions described in Examples 1C and 2C. The only
10 modification was the use of distinct peroxidase-conjugated goat antibodies specific for guinea-pig isotype IgG1 (Nordic, ref.: GAGp/IgG1/PO) or IgG2 (Nordic, ref.: GAGp/IgG2/PO), diluted 1/3.000 in PBS-Tween-milk.

5D - Serological results

15

Anti-CPpp antibodies (Figure 11a)

As previously observed, the humoral response induced against CPpp was dose-dependent: only 3 out of 5 guinea-pigs immunized with 10^5 CCID₅₀ of purified
20 ALVAC-Luc (vCP297) (group #2) weakly seroconverted to CPpp, whereas all animals (5 out of 5) that received 10^6 CCID₅₀ of the purified virus (group #3) developed a CPpp-specific response, and at much higher levels (mean ELISA titer in group #3 ~ 2 logs higher than in group #2).

- 25 The anti-CPpp titers elicited by the pelleted fraction of the inactivated ALVAC-Luc (group #4) were similar to those induced by the non-inactivated virus at equivalent protein quantity (group #3).

Surprisingly, the supernatant of inactivation of vCP297 (group #5) was also able to
30 mount an antibody response to the canarypox, and the titers induced were the highest observed in this assay. In particular, such a response differed in average by +0.6 and +0.9 log, on week 4 and 8 respectively, with that elicited by the non-inactivated purified virus (group #3). The high protein content present in this supernatant - measured subsequently

to inoculation - reaching $\sim 1 \mu\text{g}$ versus $0.55 \mu\text{g}$ for both the non-inactivated virus (group #3) or the pelleted fraction of the inactivated virus (group #4) could account for such results.

5 *Anti-gp160MN/LAI antibodies (Figure 11b)*

Anti-gp160MN/LAI antibodies were elicited in all animals during the four weeks following the first injection. For each guinea pig, an anamnestic response was noticeable after the gp160 booster injection.

10

While no significant difference in anti-gp160 antibody titers was detected between the five groups of guinea pigs after the primo-immunization, an enhancement of the humoral response to the HIV antigen was observed in some groups after the second inoculation. Indeed, by variance analysis using the Dunnett's t-test, the gp160-specific ELISA titers were found to be significantly higher in groups #3 and #4 than in group #1 (mean titers on week 8 in both groups #3 and 4 raised by $+0.7$ log as compared to group #1). In other words, these findings indicated that purified ALVAC-Luc, either inactivated or not, at protein quantity corresponding to 10^6 CCID₅₀ of infectious virus, had a significant adjuvant effect on the anti-gp160 antibody secondary response.

20

Priming with gp160 and purified ALVAC-Luc at 10^5 CCID₅₀ (group #2) also increased the anti-gp160 response (mean titers on week 8 raised by $+0.4$ log as compared to group #1), but such a stimulation was not found to be significant using the Dunnett's t-test.

25 By contrast, a significant adjuvant effect was detected in group #5, co-injected with gp160MN/LAI and the supernatant of inactivated purified ALVAC-Luc, (mean titers on week 8 raised by $+0.5$ log as compared to group #1), in accordance with the high protein content of ALVAC-Luc origin found in the supernatant.

30 Noticeably, the stimulating effect on the anti-gp160 humoral response associated to ALVAC-Luc, or products derived from it, was not found to be strictly related to the intensity of the anti-CPpp antibody response elicited. This confirms previous observations in Example 1, showing that high anti-CPpp titers were inversely related to

anti-gp160 antibody levels, probably as a consequence of antigenic competition between the HIV glycoprotein and the high doses of ALVAC injected.

IgG1 and IgG2 isotypic profiles of the anti-gp160 antibody response

5

The co-injection of gp160 and ALVAC-Luc, either inactivated or not (at protein quantity corresponding to 10^6 CCID₅₀ of infectious virus), was found to significantly increase the anti-gp160 antibody response of the IgG2 isotype, but not of the IgG1 one. Such an elevated IgG2 response was detected neither in group #2, that received gp160MN/LAI and 10^5 CCID₅₀ of purified recombinant canarypox, nor in group #5, injected with gp160MN/LAI and the supernatant of inactivated ALVAC-Luc.

General conclusion

- 15 The data presented herein confirm those obtained in Example 1 with purified CPpp, showing that purified recombinant canarypox ALVAC-Luc (vCP297), when co-injected with gp160MN/LAI at the dose of 10^6 CCID₅₀ in guinea-pig, had also the capacity to significantly: (1) stimulate the gp160-specific IgG secondary response; and (2) influence the isotypic profile of the anti-gp160 antibodies (increase in specific IgG2 titers).
- 20 However, this adjuvant effect was detected earlier with CPpp than with vCP297 (*i.e.*, after the primo-immunization for the former *versus* only the gp160 boost for the latter), suggesting that recombinant ALVAC-Luc might be less effective in enhancing the humoral response than the parental vector.
- 25 Infectivity of ALVAC-Luc was not required for such a stimulating effect to occur, since both the non-inactivated and heat-inactivated recombinant canarypox, at equivalent protein quantity (corresponding to that contained in 10^6 CCID₅₀ of infectious virus), induced similar enhanced anti-gp160 antibody titers.
- 30 The observation that the supernatant of inactivated purified ALVAC-Luc also displayed an adjuvant effect on the anti-gp160 antibody response was unexpected, but could be explained by its high protein content of ALVAC-Luc origin. Its ability to elicit the

highest antibody titers against CPpp but not against gp160, confirms the results obtained in Example 1 using various doses of purified ALVAC.

Altogether, these findings are in line with the previous hypothesis that the
5 canarypoxvirus induces some immunomodulating effects *in vivo*.

Example 6: Immunogenicity and efficacy of a detergent-splitted monovalent A/Texas
flu vaccine in the absence or presence of canarypox (ALVAC) in mice

10 The experiment reported in the present example 6 shows that non-recombinant ALVAC increases the immunogenicity and the efficacy of a detergent-splitted flu vaccine essentially in aged immunocompromised mice.

6A- CPpp preparation

15

CPpp preparations were achieved as described in Example 4A. The titer of the stock CPpp preparation is $1.6 \cdot 10^9$ CCID 50/ml

6B- Detergent-splitted monovalent A/Texas flu vaccine preparation

20

The detergent-splitted monovalent A/Texas flu vaccine (A/Texas) was manufactured by Connaught laboratories and dialyzed against PBS before use, to eliminate residual detergent and formol from the vaccine.

25 6C- Serological analyses

Serological analyses were carried out with blood samples collected on days -4 (4 days before the first immunization), 14 and 35. Antibodies to HA were titrated as follows:
Wells of Maxisorp F96 NUNC plates were coated with 1 µg/ml of HA in a Carbonate
30 buffer 0.1M, pH 9.6 overnight at room temperature. Plates were then blocked for 1 hour at room temperature With 200 µl of 0.1% BSA (Bovine Serum Albumin) in PBS Followed by 4 washings in washing buffer (PBS/ 0.1% Tween 20). All next incubations were carried out in a final volume of 100µl, followed by 5 washings in washing buffer.

Serial threefold dilutions of sera in dilution buffer (PBS/ 0.1% Tween 20/ 0.1% BSA) ranging from 1/100 to 1/218700 were added to the wells and incubated 60 min at 37 °C. After washings, a Sheep anti-mouse IgG1 peroxylase conjugated (Serotec) 1/15000 diluted or a Goat anti-mouse IgG2a Horseradish peroxylase conjugated (Caltag laboratories)1/30000 diluted were added to the plates and incubated for another 60 min at 37°C. The plates were further washed and incubated for 20 min with O-phenylenediamine dihydrochloride (Sigma) at 1.5mg/ml in 0.05M phosphate citrate buffer, pH 5.0 containing 0.03% sodium perborate (Sigma). The colored reactions were stopped with 50µl of 4N H₂SO₄. Absorbance was read in a Titer Multiscan plate reader at 450 nm. The antibody titers were measured as the reciprocal of the last dilution at which the absorbance was 2 fold over the background absorbance obtained with pre-immune sera.

6D- Challenge

Randomized groups of mice were challenged on day 42 with 50µl of live mouse-adapted A/Taiwan/1/86 influenza virus (H1 strain) corresponding to 5 lethal doses 50 of virus (5 LD₅₀). The infectious doses were given intranasally after slight anesthesia of mice with Isoflurane. The protective immune responses induced by the tested vaccinal compositions were assessed by means of survival yields and weight changes that is a good parameter of morbidity. Mortality and weight changes in the mice were monitored daily and every pair day respectively up to 21 days after challenge. The article Suryaprakash S and al, (1997), 96: 157-169 is cited by reference for achieving experimental challenges.

6E- Immunization

Six randomized groups of 16-to-18 month old (aged) or 2-month old (young) DBA/2 mice were each submitted to one of the immunization protocol as described in Table 6 hereinafter. Each group is constituted with 6 mice.

Table 6

Group	Primo-immunization		Boost	
	A/Texas dose (in μg)	ALVAC (CPpp) dose (in CCID 50)	A/Texas dose (in μg)	ALVAC (CPpp) dose (in CCID 50)
1	3	0	3	0
2	3	2×10^7	3	2×10^7
3	0	2×10^7	0	2×10^7

- 5 The groups were primed and boosted, via the S.C. route, with the compositions in a final volume of 0.2 ml. For immunization of group 2, A/Texas and appropriate amount of ALVAC were mixed together with appropriate amount of PBS to bring the final injected volume to 0.2 ml per mouse. The booster immunization was carried out in all groups one month later.

10

6F- Serological results

Anti A/Texas IgG1 antibodies (Figure 12)

- 15 Anti-A/Texas IgG1 antibodies were elicited during the two weeks following the first injection in 3 to 6 mice from group 1, in 5 to 6 mice from group 2, whereas no specific IgG1 were elicited in mice primed with ALVAC alone (group 3). The specific IgG1 mean titer was approximately 10 fold higher in the group of mice primed with the mixture of A/Texas and CPpp (group 1) than that observed in the group of mice given
- 20 A/Texas alone (group 2). The boost did not change the distribution pattern of specific IgG1 responses (observed in the 3 groups of mice) during the 15 days following the second injection. However, the specific IgG1 mean titers of groups 1 and 2 were ten-fold higher.

Anti A/Texas IgG2a antibodies (Figure 13)

Anti-A/Texas IgG2a antibodies were elicited during the two weeks following the first injection in 3 to 6 mice from group 1, in 5 to 6 mice from group 2, whereas no specific IgG2a were elicited in mice primed with ALVAC alone (group 3). The specific IgG2a mean titer was approximately 10 fold higher in the group of mice primed with the mixture of A/Texas and CPpp (group 1) than that observed in the group of mice given A/Texas alone (group 2). The boost did not change the distribution pattern of specific IgG2a responses (observed in the 3 groups of mice) during the 15 days following the second injection. However, the specific IgG2a mean titers of groups 1 and 2 were ten-fold higher.

General conclusion

This study clearly demonstrates an adjuvant effect of CPpp on the immunogenicity of A/Texas inoculated subcutaneously in immunocompromised aged mice. A similar enhancer supportive effect of CPpp on the immunogenicity of A/Texas is also observed in young mice. It is also worth noticing that CPpp increases both specific IgG2a and IgG1 responses in old mice immunized with the mixture of ALVAC and A/Texas; which means that CPpp could act both on TH1 (T helper 1) and TH2 (T helper 2) immune responses. Indeed, it is well understood for a man skilled in the art that the TH2 immune response correlates with the level of specific IgG1 response in mice and is featured by a rather humoral immune response, whereas the TH1 immune response correlates with the level of specific IgG2a response and is commonly featured by a cytotoxic and inflammatory immune response. In conclusion, this reveals that CPpp acts both on specific cellular and humoral immune responses, when it is concomitantly administered with an immunogenic compound.

6G- Challenge results (figures 14 and 15)

Mortality (Figure 14)

- 5 Three weeks after the boost, all the aged mice were given intranasally a lethal challenge of live influenza virus. All the 6 mice of the group 3 (group receiving CPpp alone) died during the 8 days consecutive to challenge. Only, 1 of 6 mice (16% survival rate) of the group 1 (group receiving A/Texas alone) was still alive 20 days after challenge whereas 4 of 6 mice of the group 2 (group receiving the mixture A/Texas and CPpp) (66% survival rate) were still alive. Moreover, the survival curve of group 2 clearly shows that the two deaths observed were delayed compared to those observed in groups 1 and 3 (Figure 14)

Morbidity (Figure 15)

- 15 The morbidity of mice after challenge was monitored for 20 days and assessed by the weight loss rate. The weight loss occurred shortly after the challenge in the group of mice immunized with CPpp alone (group 3) reaching up to 35% of the initial weight. Mice immunized with A/Texas alone (group 1) also showed a severe weight loss after challenge similar to that observed in group 3. The weight loss rate curve during the 20 days of the monitoring for the only one survivor of group 1 is represented in Figure 15 and clearly shows that the weight loss was fast and severe, whereas the weight recovery was much slower. On the other hand, the weight loss rate curve involving the 4 survivors of group immunized with the mixture of ALVAC and A/Texas (group 2) shows improvements over group 1. First, the maximum weight loss rate did not exceed 15% of the initial weight and second, the weight recovery was faster, since the survivors had recovered their initial weight by the end of the monitoring.

25 Although morbidity and mortality results about aged mice only are reported here, it is indicated that similar results were obtained with young mice.

30 General Conclusion

Morbidity and mortality results obtained with the live influenza challenge model are in agreement with those obtained from immunogenicity studies and show that ALVAC is

not only able to enhance the specific immune response to A/Texas but also contributes to the elicitation of a specific protective immune response, when it is co-administered with an antigen from a pathogenic micro-organism.

Claims

1. The use of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound for inducing an immune response in a vertebrate, wherein the poxvirus is able to enhance a specific immune response to the immunogenic compound.
5
2. The use according to claim 1, of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound, which comprises at least one antigenic determinant characteristic of a pathogenic microorganism or a tumor-associated antigen.
10
3. The use according to claim 2, of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound, which comprises at least one antigenic determinant characteristic of a pathogenic microorganism or a tumor-associated antigen; wherein the pharmaceutical composition induces a protective immune response against the pathogenic microorganism or the tumor.
15
4. The use according to claim 3, wherein the pharmaceutical composition is intended to treat or prevent an infectious disease induced by the pathogenic microorganism or a tumor-associated disorder.
20
5. The use according to any one of claims 1 to 4, of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound which is a peptide or a polypeptide.
25
6. The use according to claim 5, of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound, which is an HIV or influenza virus peptide or polypeptide.
30
7. The use according to claim 1, of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound, which is a recombinant DNA plasmid encoding a peptide or a polypeptide which comprises at least one antigenic

determinant characteristic of a pathogenic microorganism or a tumor-associated antigen.

5 8. The use according to claim 7, wherein the pharmaceutical composition induces a protective immune response against the pathogenic microorganism or the tumor.

9. The use according to claim 8, wherein the pharmaceutical composition is intended to treat or prevent an infectious disease induced by the pathogenic microorganism or a tumor-associated disorder.

10

10. The use according to any one of claims 7 to 9, of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound, which is a recombinant DNA plasmid encoding an HIV or Influenza virus peptide or polypeptide.

15

11. The use according to claim 1, of a poxvirus in the manufacture of a pharmaceutical composition comprising an immunogenic compound, which is an hapten coupled to a carrier molecule

20 12. The use according to any one of claims 1 to 11, wherein the poxvirus is a live virus.

13. The use according to claim 12, wherein the poxvirus is an attenuated virus.

25 14. The use according to any one of claims 1 to 11, wherein the poxvirus is an inactivated virus.

15. The use according to any one of claims 1 to 14, wherein the poxvirus does not encode any heterologous polypeptide.

30

16. The use according to any one of claims 1 to 13, wherein the poxvirus encodes an heterologous polypeptide.

17. The use according to claim 16, wherein the poxvirus encodes an heterologous polypeptide, which is selected from the group consisting of adhesion molecules, co-immunostimulatory molecules, apoptotic factors, cytokines and growth hormones.
- 5
18. The use according to claims 16 and 5 or 6, wherein the pharmaceutical composition comprises an immunogenic compound, which is a peptide or a polypeptide and, wherein the poxvirus encodes an heterologous polypeptide, which is immunologically cross-reactive with the immunogenic compound.
- 10
19. The use according to claim 18, wherein the poxvirus encodes an heterologous polypeptide, which has an amino acid sequence identical to the amino acid sequence of the immunogenic compound.
- 15
20. The use according to any one of claims 1 to 19, wherein the poxvirus is selected from the group consisting of orthopoxvirus, avipoxvirus, capripoxvirus, suipoxvirus, molluscipoxvirus, yatapoxvirus or an entomopoxvirus.
21. The use according to claim 20, wherein the poxvirus is a vaccinia virus.
- 20
22. The use according to claim 20, wherein the poxvirus is a canarypox virus.
23. A pharmaceutical composition comprising (i) an immunogenic compound and (ii) a poxvirus encoding an heterologous polypeptide which is selected from the group consisting of adhesion molecules, co-immunostimulatory molecules, chemokines apoptotic factors, cytokines and growth hormones.
- 25
24. A pharmaceutical composition according to claim 23, wherein the immunogenic compound is selected from the group consisted of a peptide, a polypeptide, a DNA plasmid encoding a peptide or a polypeptide, and an hapten coupled to a carrier molecule.
- 30

25. A pharmaceutical composition comprising (i) an immunogenic compound which is a first polypeptide, and (ii) a poxvirus encoding a second heterologous polypeptide, which has an amino acid sequence identical to the amino acid sequence of the first polypeptide.
- 5
26. A pharmaceutical composition comprising (i) an immunogenic compound which is a DNA plasmid encoding a first polypeptide, and (ii) a poxvirus encoding a second heterologous polypeptide, which has an amino acid sequence identical to the amino acid sequence of the first polypeptide.
- 10
27. A pharmaceutical composition according to claim 24, 25 or 26, wherein the first and second polypeptide polypeptide are HIV or influenza virus polypeptides.
- 15
28. A pharmaceutical composition according to any one of claims 23 to 27, further comprising a pharmaceutical acceptable diluent or carrier.

1/13

Figure 1a





Figure 1b



2/13

Figure 2a






Figure 2b



3/13

Figure 3



4/13

Figure 4a





Figure 4b



5/13

Figure 5







Figure 6






6/13

Figure 7Figure 8

7/13

Figure 9



8/13

Figure 10a





Figure 10b



9/13

Figure 11a







Figure 11b




11/13

Figure 13

12/13

Figure 14

13/13

Figure 15

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/39, 39/21, 35/76, 39/145, 39/00		A3	(11) International Publication Number: WO 00/00216 (43) International Publication Date: 6 January 2000 (06.01.00)
(21) International Application Number: PCT/EP99/04913 (22) International Filing Date: 28 June 1999 (28.06.99) (30) Priority Data: 98420110.3 26 June 1998 (26.06.98) EP 98420111.1 26 June 1998 (26.06.98) EP (71) Applicant (for all designated States except US): PASTEUR MERIEUX SERUMS ET VACCINS [FR/FR]; 58, avenue Leclerc, F-69007 Lyon (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): CHEVALIER, Michel [FR/FR]; 19, rue de la Guillotière, F-38270 Beaupaire (FR). MEIGNIER, Bernard [FR/FR]; 26, rue du 8 mai 45, F-69510 Thurins (FR). MOSTE, Catherine [FR/FR]; 7, avenue Louis Momet, F-69260 Charbonnières-les-Bains (FR). SAMBHARA, Suryaprakash [CA/CA]; 50 Harness Circle, Markham, Ontario L3S 1Y1 (CA). (74) Agent: AYROLES, Marie-Pauline; Pasteur Mérieux Sérums et Vaccins, 58, avenue Leclerc, F-69007 Lyon (FR).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 16 March 2000 (16.03.00)
(54) Title: USE OF POXVIRUSES AS ENHANCER OF SPECIFIC IMMUNITY			
(57) Abstract <p>The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine <i>e.g.</i>, a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 99/04913

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K39/39 A61K39/21 A61K35/76 A61K39/145 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A. MAYR ET AL.: "BEKÄMPFUNG DES ECTHYMA CONTAGIOSUM (PUSTULARDERMATITIS) DER SCHAFE MIT EINEM NEUEN PARENTERAL-ZELLKULTUR-LEBENDIMPFSTOFF." ZENTRALBLATT FÜR VETERINÄRMEDIZIN, REIHE B, vol. 28, no. 7, 1981, pages 535-552, XP002086053 BERLIN, DE page 545, paragraph 4 -page 546, paragraph 2	1-4, 14, 15, 20
X	WO 95 22978 A (A. MAYR) 31 August 1995 (1995-08-31) page 15, line 24 -page 16, line 6; claims; figure 2; examples 6,10; table 3 page 20, line 1 - line 18 --- -/--	1-5, 12-16, 20-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 1999

Date of mailing of the international search report

12/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/04913

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 40268 A (AMERICAN HOME PRODUCTS CORPORATION) 19 December 1996 (1996-12-19) page 6, paragraph 4 -page 7, line 3; claims 1-5,12,13 ---	1-5,7-9, 12-15, 20-22
Y	A. MAYR ET AL.: "VERGLEICHENDE UNTERSUCHUNGEN ÜBER DIE IMMUNSTIMULIERENDE (PARAMUNISIERENDE) WIRKSAMKEIT VON BCG, LEVAMISOL, CORYNEBACTERIUM PARVUM UND PRÄPARATEN AUS POCKENVIREN IN VERSCHIEDENEN "IN VIVO"- UND "IN VITRO"-TESTEN." ZENTRALBLATT FÜR VETERINÄRMEDIZIN, REIHE B, vol. 33, 1986, pages 321-339, XP002039313 page 321; table 10 page 322, paragraph 5 -page 323, line 6 ---	1-28
Y	WO 93 08836 A (INSTITUT PASTEUR) 13 May 1993 (1993-05-13) page 3, line 4 - line 8; claims 1-4,8,28-30,39-42,46,49,50 page 13, line 12 - line 30 page 16, paragraph 4 -page 17, paragraph 3 ---	1-28
Y	WO 95 27507 A (VIROGENETICS CORPORATION) 19 October 1995 (1995-10-19) cited in the application page 24, line 1 -page 26, line 16; claims; examples 13,14 page 31, line 19 - line 30 ---	1-28
A	M.L. CLEMENTS-MANN ET AL.: "IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPE 1 INDUCED BY CANARYPOX EXPRESSING HIV-1mn gp120, HIV-1sf2 RECOMBINANT gp120, OR BOTH VACCINES IN SERONEGATIVE ADULTS." THE JOURNAL OF INFECTIOUS DISEASES, vol. 177, no. 5, May 1998 (1998-05), pages 1230-1246, XP000857785 CHICAGO, US page 1243, right-hand column, paragraph 3 -----	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/04913

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9522978 A	31-08-1995	DE 4405841 C	05-01-1995
		AT 153242 T	15-06-1997
		AU 690625 B	30-04-1998
		AU 1416795 A	11-09-1995
		BR 9506882 A	19-08-1997
		CA 2182207 A	31-08-1995
		CN 1142187 A	05-02-1997
		DE 59402826 D	26-06-1997
		DK 669133 T	14-07-1997
		EP 0669133 A	30-08-1995
		ES 2102081 T	16-07-1997
		FI 963277 A	22-08-1996
		GR 3023508 T	29-08-1997
		HU 75545 A	28-05-1997
		JP 2873880 B	24-03-1999
		JP 9504803 T	13-05-1997
		NO 963462 A	20-08-1996
		NZ 278079 A	26-01-1998
		PL 316024 A	23-12-1996
		SI 669133 T	31-10-1997
WO 9640268 A	19-12-1996	US 5820869 A	13-10-1998
		AU 699794 B	17-12-1998
		AU 5973196 A	30-12-1996
		BR 9609089 A	02-02-1999
		CA 2224257 A	19-12-1996
		EP 0831921 A	01-04-1998
		JP 11506614 T	15-06-1999
WO 9308836 A	13-05-1993	AU 2800392 A	07-06-1993
		CA 2122263 A	13-05-1993
		EP 0613378 A	07-09-1994
		JP 7501052 T	02-02-1995
		US 5876724 A	02-03-1999
WO 9527507 A	19-10-1995	US 5863542 A	26-01-1999
		AU 702634 B	25-02-1999
		AU 2275595 A	30-10-1995
		CA 2187031 A	19-10-1995
		EP 0752887 A	15-01-1997
		JP 9511649 T	25-11-1999